GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40823)

  • GC81857 structure
    GC81857Sulbactam-d₂
    CAS: 77741-83-4
    Purity: >98.00%

    Sulbactam -d 2 (CP45899-d 2 ) is the deuterated-labeled Sulbactam.

  • GC81858 structure
    GC81858SuO-Glu-Val-Cit-PAB-MMAE-d₈-1
    Purity: >95.50%

    SuO-Glu-Val-Cit-PAB-MMAE -d 8 -1 (NHS-Glutarate-Val-Cit-PAB-MMAE-d 8 -1) is the deuterated-labeled SuO-Glu-Val-Cit-PAB-MMAE.

  • GC81859 structure
    GC81859TH-Z827 diTFA
    Purity: >98.00%

    TH-Z827 diTFA is a selective KRAS G12D inhibitor that exhibits activity against GDP-bound and GMPPNP-bound KRAS G12D, but shows no activity against KRAS (WT) and KRAS G12C.

  • GC81860 structure
    GC81860UBA6-IN-1 hydrochloride
    CAS: 1557138-61-0
    Purity: >98.00%

    UBA6-IN-1 hydrochloride is a UBA6/UBE1L2 inhibitor ( IC 50 ≤50 nM) that acts by reducing the level of squalene epoxidase ( SQLE ).

  • GC81861 structure
    GC81861Vancomycin-d₁₀ acetate
    Purity: >98.00%

    Vancomycin-d 10 acetate is the deuterated-labeled Vancomycin acetate.

  • GC81862 structure
    GC81862YJ1206 TFA
    Purity: >98.00%

    YJ1206 TFA is an orally active selective CDK12 / CDK13 PROTAC degrader.

  • GC81863 structure
    GC818632A/2B Dengue protease substrate acetate
    Purity: >98.00%

    2A/2B Dengue protease substrate (Ac-RTSKKR-pNA) acetate is a peptide substrate for the Dengue NS2B-NS3 protease, with a K i value of 12 μM.

  • GC81864 structure
    GC818643BP-3580 TFA
    Purity: >98.00%

    3BP-3580 TFA (compound 11) is a conjugate targeting FAP that binds to FAP-positive cells via the FAPI moiety and internalizes, delivering the payload to FAP -expressing cells, thereby inhibiting RA FLS proliferation, migration, and invasion, reducing inflammatory cytokine expression, and suppressing pannus formation.

  • GC81865 structure
    GC81865(7S)-Nivegacetor
    CAS: 2443491-73-2
    Purity: >98.00%

    (7S)-Nivegacetor ((7S)-RG6289) is an isomer of Nivegacetor.

  • GC81866 structure
    GC818668-Azidooctan-1-amine
    CAS: 867338-63-4
    Purity: >98.00%

    8-Azidooctan-1-amine is a PROTAC linker that can be used in PROTAC synthesis-related research, such as L013 [1] .

  • GC81867 structure
    GC81867Ac-ETDK(myr)-AMC acetate
    Purity: >98.00%

    Ac-ETDK(myr)-AMC acetate is a DLAT-derived ε-N-myristoyllysine peptide substrate for fatty-acid deacylase HDAC11, used in fluorescence-based HDAC11 activity assays.

  • GC81868 structure
    GC81868Acetyl-pepstatin ammonium
    Purity: >98.00%

    Acetyl-pepstatin ammonium is an aspartic protease ( PRs ) inhibitor that targets HIV-1 protease and XMRV protease with K i values of 13 nM and 712 nM, respectively.

  • GC81869 structure
    GC81869APP669-711 acetate
    Purity: >98.00%

    APP669-711 acetate is an N-terminally extended amyloid β peptide ( Aβ (-3)-40) that forms amyloid fibrils and co-deposits with Aβ in brain plaques, and also serves as a plasma biomarker for assessing brain Aβ load.

  • GC81870 structure
    GC81870Bethanidine hydriodide
    CAS: 2863-34-5
    Purity: >98.00%

    Bethanidine hydriodide is an orally active antihypertensive agent and adrenergic neuron blocker.

  • GC81871 structure
    GC81871CAP 6 m7G(LNA)(5')ppp(5')(2'OMeA)pG trisodium solution (100 mM ± 3 mM)
    Purity: >98.00%

    CAP 6 m7G(LNA)(5')ppp(5')(2'OMeA)pG trisodium solution (100 mM ± 3 mM) is a monomeric raw material that can be used for nucleic acid synthesis.

  • GC81872 structure
    GC81872CPTH2-d₄
    Purity: >98.00%

    CPTH2 -d 4 is the deuterated-labeled CPTH2.

  • GC81873 structure
    GC81873Ciprofloxacin hydrochloride
    CAS: 86483-48-9
    Purity: >98.00%

    Ciprofloxacin hydrochloride (Bay-09867 hydrochloride) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent.

  • GC81875 structure
    GC81875Histone H3 (1-25), amide acetate
    Purity: >98.00%

    Histone H3 (1-25), amide acetate is a synthetic N-terminal tail peptide derived from histone H3, which can be used to identify substrates of histone methyltransferases (HMTs).

  • GC81876 structure
    GC81876Imlunestrant-d₄
    Purity: >98.00%

    Imlunestrant -d 4 (LY-3484356-d 4 ) is the deuterated-labeled Imlunestrant.

  • GC81879 structure
    GC81879NCP26 TFA
    Purity: >99.50%

    NCP26 TFA is an ATP-competitive ProRS inhibitor (with a K D of 271 nM in the absence of proline, and a K D of 0.35 nM in the presence of 100 μM proline).

  • GC81880 structure
    GC81880OSU-2S TFA
    Purity: >98.00%

    OSU-2S TFA is a non-immunosuppressive derivative of Fingolimod hydrochloride (FTY720).

  • GC81882 structure
    GC81882PROTAC CARM1 degrader-1 TFA
    Purity: >98.00%

    PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC 50 of 8.1 nM in MCF‑7 cells.

  • GC81883 structure
    GC81883(R)-AR/BRD4 RIPTAC-1
    CAS: 3083307-47-2
    Purity: >98.00%

    (R)-AR/BRD4 RIPTAC-1 is the R-enantiomer of AR/BRD4 RIPTAC-1.

  • GC81884 structure
    GC81884(R)-Vanzacaftor-d₄
    Purity: >98.00%

    (R)-Vanzacaftor -d 4 ((R)-VX-121-d 4 ) is the deuterated-labeled (R)-Vanzacaftor.